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Abstract
Background: Traumatic injury is the fourth leading cause of death globally. Half of all trauma deaths are due to
bleeding and most of these will occur within 6 h of injury. Haemorrhagic shock following injury has been shown to
induce a clotting dysfunction within minutes, and this early trauma-induced coagulopathy (TIC) may exacerbate
bleeding and is associated with higher mortality and morbidity. In spite of improved resuscitation strategies over
the last decade, current transfusion therapy still fails to correct TIC during ongoing haemorrhage and evidence for
the optimal management of bleeding trauma patients is lacking. Recent publications describe increasing the use of
Viscoelastic Haemostatic Assays (VHAs) in trauma haemorrhage; however, there is insufficient evidence to support
their superiority to conventional coagulation tests (CCTs).
Methods/design: This multicentre, randomised controlled study will compare the haemostatic effect of an
evidence-based VHA-guided versus an optimised CCT-guided transfusion algorithm in haemorrhaging trauma
patients. A total of 392 adult trauma patients will be enrolled at major trauma centres. Participants will be eligible if
they present with clinical signs of haemorrhagic shock, activate the local massive haemorrhage protocol and initiate
first blood transfusion. Enrolled patients will be block randomised per centre to either VHA-guided or CCT-guided
transfusion therapy in addition to that therapy delivered as part of standard care, until haemostasis is achieved.
Patients will be followed until discharge or 28 days. The primary endpoint is the proportion of subjects alive and
free of massive transfusion (less than 10 units of red blood cells) at 24 h. Secondary outcomes include the effect of
CCT- versus VHA-guided therapy on organ failure, total hospital and intensive care lengths of stay, health care
resources needed and mortality. Surviving patients will be asked to complete a quality of life questionnaire
(EuroQol EQ-5DTM) at day 90.
Discussion: CCTs have traditionally been used to detect TIC and monitor response to treatment in traumatic major
haemorrhage. The use of VHAs is increasing, but limited evidence exists to support the superiority of these
technologies (or comparatively) for patient-centred outcomes. This knowledge gap will be addressed by this trial.
Trial registration: ClinicalTrials.gov, ID: NCT02593877. Registered on 15 October 2015.
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Background
Traumatic injury is responsible for a large and increasing
proportion of the world’s burden of disease and is the
fourth leading cause of death globally [1]. Half of all trauma
deaths are due to bleeding and most of these will occur
within 6 h from injury [2]. Haemorrhagic shock following
injury has been shown to induce a clotting dysfunction (i.e.
coagulopathy) within minutes [3–5]. Such early trauma-
induced coagulopathy (TIC) may exacerbate bleeding and
is associated with higher mortality and morbidity [4, 6, 7].
Many more injured patients will go on to develop different
types of coagulopathy at different times during the course
of their treatment, either as a result of their body’s ongoing
response to trauma or as a consequence of their clinical
care. Coagulopathic, haemorrhaging trauma patients have
increased blood transfusion requirements, increased mor-
tality and more adverse outcomes [8]. Despite improve-
ments in surgical techniques, resuscitation strategies and
intensive care treatments, outcomes for critically injured
patients remain poor [9]. Within the last decade research
focussing on TIC has led to improved resuscitation strat-
egies, resulting in the early and more aggressive use of
blood products and coagulation factors for the manage-
ment of massively bleeding patients.
In spite of improved resuscitation strategies, current
transfusion therapy still fails to correct coagulopathy
during ongoing haemorrhage [10, 11]. The mechanisms
and genesis of TIC have yet to be fully elucidated, and
there are many questions about how to optimally diag-
nose, resuscitate and monitor the critically bleeding
trauma patient. It is important to detect TIC as early as
possible. Conventional coagulation tests (CCT), such as
prothrombin time/international normalised ratio (PT/
INR), activated partial thromboplastin time (APTT), fi-
brinogen concentration and PLT, have traditionally been
used. However, there is a striking lack of evidence to
support the use of these CCTs to monitor resuscitation,
although threshold triggers for intervention based on
CCTs have been suggested [5]. Recent published evi-
dence describes an increasing recognition for the poten-
tial of the two current market-leading Viscoelastic
Haemostatic Assays (VHAs) namely thromboelastogra-
phy (TEG®; Haemonetics Incorporation) and rotational
thromboelastometry (ROTEM®; TEM Innovation
GmbH). Both platforms use similar test modes to rapidly
and accurately determine the functional coagulation
status of patient whole blood. However, the evidence
base supporting a role for these VHA devices is lim-
ited, and less attention has been directed to under-
standing their cost-effectiveness. Cost-effectiveness
may be particularly relevant both in the context of
additional therapeutic interventions required, but also
in potential savings, if fewer treatments are required
based on delivery of individualised assessments of
haemostasis.
The relative contribution of blood components, such
as fibrinogen and platelets, to clot strength can be evalu-
ated through the use of specific inhibitors or agonists
[12]. The viscoelastic properties of blood samples are re-
corded under low shear conditions, thereby providing a
comprehensive visual profile of clot formation and
breakdown (fibrinolysis).
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Unlike laboratory-based CCTs which might take more
than 60 min for the results to be available to clinicians
[8], VHA is a point-of-care device which might provide
clinically relevant results within even 5–10 min and thus
may be repeated in a massive bleeding situation to iden-
tify patient-specific needs for transfusion components in
a timelier manner. Furthermore, VHAs provide the po-
tential to detect hyperfibrinolysis, and possibly hyperco-
agulability. However, VHA assays and testing have costs,
require training and additional oversight, and may not
provide insight into other potentially important haemo-
static derangements at the endothelial or platelet level.
In addition, other publications attest to how changes in
the process and pathways for the delivery of CCTs can
be modified and accelerated [13, 14].
Whilst VHA has been used for many years in liver
transplant and cardio-pulmonary surgery, robust data
supporting its universal uptake in the context of trauma
are lacking. Whilst some publications have attempted to
identify VHA patterns and thresholds characterizing
TIC and the need for massive transfusion in trauma pa-
tients, definitive evidence proving its superiority over
CCTs in the diagnosis and management of coagulopathy
in the acute setting is not available [15–18].
Although considered a preventable major cause of
death, the management of coagulopathic bleeding in
trauma patients remains primarily based upon retro-
spective registry studies of survival and extrapolating the
results of transfusion practice performed in the elective,
non-acute surgical setting. Treatment is diverse com-
prising the empiric transfusion of red blood cells (RBC)
and clotting product supplements to patients, blind to
the type and severity of TIC they may have – or indeed
even if they do not have coagulopathy. It is well estab-
lished that blood transfusion carries significant health
risks both related to transmission of pathogens and to
the development of transfusion reactions. Published in
2015, the results of the Pragmatic, Randomised Optimal
Platelet and Plasma Ratios (PROPPR) trial [19] provide
the best evidence to date for optimal trauma haemor-
rhage resuscitation. PROPPR demonstrated that an em-
piric massive transfusion protocol (MTP) aiming at a
ratio of 1:1:1 of blood components (RBC 1: plasma 1:
platelets 1) administered from the early phase of care
and during ongoing haemorrhage was associated with
fewer exsanguinations in the initial 24 h (p = 0.03) and a
tendency towards improved 24-h survival (p = 0.12) than
a 1:1:2 ratio.
The present prospective randomised controlled trial (RCT)
will employ evidence-based treatment algorithms to compare
outcomes of VHA-guided resuscitation versus CCT resusci-
tation support in haemorrhaging trauma patients.
The hypothesis for this comparative study is that
VHA-directed therapy will enhance early haemostatic
control by the targeted correction of TIC, whilst also re-
ducing the total amount of blood products and procoa-
gulants administered to all bleeding trauma patients,
including those not having TIC. This would significantly
reduce both the number of patients receiving blood
transfusion and the number of transfused blood prod-
ucts per transfused patient, thereby improving both pa-
tient safety and resource utilisation.
Methods/design
This is an investigator-initiated, multi-centred, superior-
ity, parallel-group, randomised controlled trial per-
formed at eight major trauma centres. The trial sites
include: Rigshospitalet (Copenhagen, Denmark), Aca-
demic Medical Centre (Amsterdam, The Netherlands),
Oslo University Hospital (Oslo, Norway), Kliniken der
Stadt Köln gGmbH Cologne, Germany), The Royal
London Hospital (London, UK), John Radcliffe Hospital
(Oxford, UK). Nottingham University Hospitals, Queen’s
Medical Centre (Nottingham, United Kingdom) and
University of Kansas Hospital (UKH) (Kansas City, MO,
USA) are planning to start recruitment in 2017.
This protocol (Additional file 1) conforms to the Con-
solidated Standard of Reporting Trials (CONSORT)
guidelines. Figure 1 shows the Standard Protocol Items:
Recommendation for Interventional Trials (SPIRIT)
schedule of enrolment, interventions and assessments.
The SPIRIT Checklist is given in the Additional file 2.
An overview of the study process is provided in Fig. 2
(study scheme).
Inclusion criteria
Adult trauma patients (according to local definitions)
will be enrolled if they present with clinical signs of
haemorrhagic shock, according to the responsible
trauma team leader, activate the local massive haemor-
rhage protocol, according to the participating institu-
tions’ specific routines, and initiate first transfusion.
Participants must be randomised within 3 h of injury
and 1 h of admission to the ED of the participating study
site. Agreement is provided on behalf of incapacitated
patients by a personal consultee (PC) or a nominated
consultee (NC).
Exclusion criteria
There are no exclusion criteria.
Primary objective
The primary objective is to compare the haemostatic ef-
fect of VHA assay-guided transfusion strategy versus
optimised CCT-guided transfusion strategy in haemor-
rhaging trauma patients.
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Secondary objective
The secondary objectives of the study are to determine
the effects of VHA-led versus optimised CCT-guided re-
suscitation on organ failure, hospital length of stay (LOS),
intensive care unit (ICU) stay, duration of mechanical
ventilation, health care resource needs and mortality.
Primary endpoint
The primary endpoint is the proportion of subjects alive
and free of massive transfusion (less than 10 units of
RBC transfused) at 24 h post admission.
Secondary endpoints
The secondary endpoints listed below will be analysed in
order to provide a sensitive and comprehensive descrip-
tion of outcomes and health care resource demands for
the VHA and CCT arm subjects:
 All-cause mortality at 6 and 24 h and 28 and
90 days post admission
 Duration and severity of coagulopathy until
haemostasis, as defined by the area under the time
multiplied by Prothrombin Ratio (PTr) curve, with
coagulopathy defined as PTr > 1.2. Patients who die
will have their time of haemostasis set at 24 h, and
last PTr extrapolated to this time point
 Proportion of patients who have corrected
coagulopathy, defined as PTr < 1.2, after first 8 units
of RBC
 Time to haemostasis (defined as having occurred at
the end of the first hour free of red cell transfusions
and the treating clinicians believe primary
haemostasis has been achieved)
 Time spent in coagulopathic condition, defined as
PTr ≥ 1.2, until haemostasis, defined as the point 1 h
Fig. 1 Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) schedule of enrolment, interventions and assessments
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from the last administration of RBC and the treating
clinician believes that primary haemostasis has been
achieved
 Blood products administered (RBC, plasma, platelets
alone and in total) within first 6 and 24 h after
admission
 28-day ventilator-free and ICU-free days (patients
who die in hospital during the 28-day study period
will be considered to have zero hospital-free days)
 Total hospital length of stay
 28-day symptomatic thromboembolic events defined
as: deep venous thrombosis (DVT) diagnosed by
compression ultrasound or venography, pulmonary
embolism diagnosed by computed tomography (CT)
pulmonary angiogram or ventilation-perfusion scan
or myocardial infarction and/or stroke identified by
standard clinical diagnostic investigation(s)
 Incidence of transfusion-related complications
 Incidence of organ dysfunction, defined by
Sequential Organ Failure Assessment (SOFA) score
 Health care resource, productivity costs and HRQoL
(EuroQol EQ-5DTM at discharge or day 28, and at
day 90)
 Lifetime health economic cost-effectiveness of perso-
nalised VHA-guided haemorrhagic treatment versus
MTP-based on best practice and CCTs
Fig. 2 Study scheme
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Study procedures
Screening procedures
Local investigators will identify eligible adult trauma pa-
tients with haemorrhagic shock and ongoing bleeding as
soon as possible after the patient has arrived in the
emergency department (ED), using local transfusion trig-
gers. If patients are deemed to be eligible, consent for
entry into the trial will be sought. A screening log will
be completed once a week, which will record all patients
considered for eligibility to the trial by the investiga-
tor(s). The log will include age, gender, inclusion/exclu-
sion criteria and other reasons for non-enrolment. The
screening log data will be reviewed at regular intervals.
Randomisation procedure
Enrolled patients will be block randomised per centre to
either the CCT or the VHA study arm within 3 h of injury
and within 1 h of admission. The trial will be un-blinded
for clinical staff and site investigators. Once a patient is
determined eligible for the study and informed consent or
agreement has been obtained, each subject will be enrolled
as soon as possible and will be assigned a unique alpha-
numeric study identifier. Randomisation will be performed
by the site investigator opening a sealed envelope contain-
ing the randomised treatment group, to allow for immedi-
ate allocation of subjects. An independent party,
appointed by the sponsor, will generate the randomisation
sequence and site envelopes centrally.
Schedule of intervention
All participating centres will initiate the management of
the study population according to standard local proto-
cols regardless of enrolment in the trial. Following ran-
domisation, study participants will undergo
interventions at set time points as outlined in Fig. 1
(Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) schedule of enrolment, inter-
ventions and assessments) and be followed up for
90 days after enrolment.
Standard care
All participating centres currently manage critically
bleeding trauma patients according to a standardised
MTP aiming at a ratio of RBC 1: plasma 1: platelets 1
(1:1:1), typically administering plasma from the start of
resuscitation and platelets immediately as they become
available. Tranexamic acid (TXA) will be administered
to all patients as an intravenous bolus of 1 g over
10 min (either pre-hospital or in the ED) followed by an
intravenous infusion of 1 g over 8 h, providing that the
patient is less than 3 h post injury.
Current use of additional diagnostics and therapy,
such as systematic approach according to Advanced
Trauma Life Support (ATLS®) principles, early imaging
(e.g. X-rays, Focussed Assessment with Sonography for
Trauma (FAST), computer tomography (CT)), activation
criteria for MTP, surgical approach applying damage
control principles when indicated, the availability and
use of interventional radiology, will not be affected in ei-
ther of the study groups. An optimised initial MTP
based on a 1:1:1 balanced transfusion will be imple-
mented in all centres for approximately 2 months prior
to initiation of the RCT and standardised as far as local
routines and blood product availability allow.
Initiation of study care
Corresponding and optimised algorithms based on VHA
trigger parameters for the VHA arm and CCT results
for the CCT arm, respectively, have been developed and
will be applied in the enrolled subjects (Fig. 3a, b, c).
During active haemorrhage, samples will be taken for
CCT/VHA analysis at baseline and after every 4 units of
RBC until haemostasis. The results from each blood
sample will be acted upon as soon as they are available.
For the VHA arm, this implies acting upon the parame-
ters as they are appearing, not waiting until the VHA
trace is completed.
If a planned study intervention has not yet been adminis-
tered, the sample will be taken and analysed (where re-
sources allow) but will not be used to guide study
intervention. The first sample taken after a study interven-
tion is actually administered will be the next sample used to
guide study intervention based upon the respective protocol.
The same blood products and procoagulants will be
employed in both study arms, with existing standard
practice in all participating centres being closely aligned
to that of the CCT arm. Trial products will be given as
an addition to the 1:1:1 baseline MTP and TXA. The
procoagulants included in the algorithms are fibrinogen
concentrate or cryoprecipitate and additional platelets,
plasma and TXA.
Enrolled patients will be block randomised per centre
to either study arm:
 CCT: haemostatic resuscitation (standard care),
based on a MTP aiming at ratio 1:1:1 of blood
components (RBC 1: plasma 1: platelets 1) and
TXA, and CCTs to guide further resuscitation with
blood products and procoagulant factors
 VHA: haemostatic resuscitation (standard care),
based on a MTP aiming at ratio 1:1:1 of blood
components (RBC 1: plasma 1: platelets 1) and
TXA, and VHA-guiding further resuscitation with
blood products and procoagulant factors
Randomised study care – VHA arm
VHA will be conducted for all subjects in the VHA arm
at each time point up to 24 h. During active
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haemorrhage, samples will be taken for VHA analysis
at baseline and after every 4 units of RBC until
haemostasis. The clinical course of subjects rando-
mised to the VHA arm will follow a treatment algo-
rithm utilizing VHA results (Fig. 3a and b). The
subject will be treated with standard haemostatic re-
suscitation based on a MTP aiming for 1:1:1 ratio of
blood components and initial TXA. In addition, ac-
cording to threshold values in the algorithms, the
subjects will be given fibrinogen concentrate or cryo-
precipitate and/or additional platelets, plasma and
TXA depending on the VHA results.
Fibrinogen concentrate or cryoprecipitate will be ad-
ministrated when FIBTEM Clot Amplitude at 5 min
(CA5) is below 10 mm or functional fibrinogen (FF)
TEG® Maximum Amplitude (MA) is below 20 mm. Add-
itional platelets are indicated when the subtracted ampli-
tude of FIBTEM CA5 from EXTEM CA5 is below
30 mm, or the subtracted amplitude of FF TEG® MA
from rapid TEG® MA is below 45 mm. Additional
plasma is indicated when the results show a normal
EXTEM CA5, defined as above 40 mm, but still a pro-
longed EXTEM clotting time (CT), defined as above
80 s, or normal rapid TEG® MA, defined as above
65 mm, but still a prolonged rapid TEG® activated clot-
ting time (ACT), defined as above 120 s. Additional
TXA is indicated when the EXTEM Lysis Index at
30 min (LI30) is below 85% or rapid TEG® clot lysis at
30 min (Ly30) is above 10%.
This VHA treatment algorithm is based upon analysis
of more than 2200 trauma subjects enrolled to a pro-
spective observational study conducted at the participat-
ing study sites, entitled Activation of Coagulation and
Inflammation in Trauma (ACIT). Analysis of the ACIT
dataset has enabled the definition of clinically relevant
VHA thresholds and patterns by which it is possible to
rapidly identify coagulopathic patients and anticipate the
need for massive transfusion. These threshold parame-
ters have been applied to the generation of an evidence-
based targeted treatment algorithm.
According to pre-designation, each study centre will
only conduct VHA using either thromboelastography
(TEG®) or rotational thromboelastometry (ROTEM®) to
determine the following parameters:
 TEG®: RapidTEG® ACT, MA and Ly30; functional
fibrinogen TEG® MA
 ROTEM®: EXTEM CT, CA5 and Li30; FIBTEM
CA5
Randomised study care – CCT arm
CCTs will be conducted for all subjects in the CCT arm
at each time point up to 24 h. The tests will comprise
platelet counts (PLT), activated partial thromboplastin
time (aPTT), prothrombin time – international normal-
ised ratio (PT/INR) and Clauss fibrinogen assay. PTr
and Clauss fibrinogen will be measured for all study sub-
jects at each time point.
a b c
Fig. 3 Algorithms
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The clinical course of subjects randomised to the CCT
arm will follow a treatment algorithm utilizing CCT re-
sults (Fig. 3c) and based upon current published evi-
dence and empiric best practice according to the
PROPPR and CRASH-2 trials data (i.e. a 1:1:1 product
ratio, with the anti-fibrinolytic TXA) [19–21]. The sub-
ject will be treated with standard haemostatic resuscita-
tion based on a MTP aiming for a 1:1:1 ratio of blood
components and initial TXA. In addition, the subjects
will be given fibrinogen concentrate or cryoprecipitate
and/or additional platelets and plasma depending on the
CCT results.
Fibrinogen concentrate or cryoprecipitate will be in-
dicated when fibrinogen values are below 2.0 g/L.
Additional platelets will be indicated with PLT below
100 × 109/L and additional plasma will be adminis-
trated when the INR is above 1.2 despite normal fi-
brinogen, defined as 2.0 g/L or above. There are no
generally accepted indications for additional anti-
fibrinolytic therapy using CCTs.
Detail of outcome measures collected
SOFA score (Additional file 3)
SOFA score will be registered until discharge from ICU.
Blood products and procoagulants
Timings, total number (and doses if appropriate) of dif-
ferent blood products and procoagulants administered
both pre-hospital and after admission to the study
centre, during resuscitation and after 6 and 24 h will be
recorded including:
 RBC, fresh frozen plasma (FFP)/Octaplas,
cryoprecipitate, platelets, whole blood and/or
autologous RBC from cell salvage
 Coagulation factor concentrates (prothrombin
complex concentrate (PCC), fibrinogen, activated
recombinant factor VII (rFVIIa))
 TXA
Fluids
Timings (during first 24 h only) and total volume of dif-
ferent fluids administered both pre-hospital and after ad-
mission to the study centre until 24 h will be recorded
including crystalloids, colloids and hypertonic saline.
Thromboprophylaxis/prothrombotic medication
Type of medication administered, timings, dose and in-
dication will be recorded daily until day 28 with particu-
lar attention to duration of treatment (stop date).
Bleeding episodes
Qualifying episodes will be defined by radiological evi-
dence, like contrast extravasation on CT scan, and/or
clinical suspicion, like haemodynamic instability, com-
bined with transfusion requirement after initial haemo-
stasis (defined as the point 1 h from the last
administration of RBC and the treating clinician believes
primary haemostasis has been achieved).
Ventilator-free days
Calculated by the subtracting the number of days spent
on mechanical ventilation from 28. Death before day 28,
recorded as 28.
Vasopressor days
Calculated as the total number of days spent on ino-
tropic drugs, including for instance noradrenaline, dobu-
tamine, vasopressin.
Renal replacement therapy days
Calculated as the number of days spent on haemodialy-
sis or haemofiltration.
ICU days
The total length of stay in the ICU. If the patient is in
the ICU at any time point during a calendar day, this
day will be considered an ICU day.
Length of stay
Length of stay will be recorded in days, for the total
number spent in ICU and in hospital. If the patient is in
the hospital at any time point during a day, this day will
be considered a hospital day.
Surgical episodes
Description, timing, duration and reasons for all surgical
episodes will be recorded. This includes interventional
radiology and bedside surgical interventions in addition
to major surgical procedures.
Thromboembolic events
Symptomatic venous thromboembolic events will be re-
corded, as confirmed by either compression ultrasound/
venography (DVT or by CT – pulmonary angiogram/
ventilation – perfusion scan (pulmonary embolism (PE)).
Other thromboembolic events, such as myocardial in-
farction and/or stroke, will be identified by standard
clinical diagnostic investigations(s).
Patient disposition
First destination after discharge and disposition at
90 days post admission will be recorded as either
home, rehabilitation facility, nursing home, other hos-
pital or other.
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Quality of life (Qol)
Subject quality of life will be assessed using the EuroQoL
EQ-5D™ questionnaire, a standardised instrument for use as
a measure of health outcome. Quality of life assessment will
be conducted in the study centre upon discharge of the
subject from hospital and at 90 days post admission.
The in-hospital (i.e. discharge) questionnaire will be
conducted by research investigators with the patient
where possible, but may also be completed with patient’s
PC if necessary. The questionnaire can be completed in
less than 5 min. Where the subject has already left hos-
pital, the questionnaire will be posted out with a return
stamped addressed envelope.
Patients who have not returned the questionnaire
within 2 weeks of the initial request will be telephoned
as a reminder to complete the questionnaire and may be
asked to complete it over the telephone if necessary.
A further EuroQoL EQ-5DTM questionnaire will be
provided to assess subject quality of life at 90 ± 5 days
post admission. Confirmation with the local (i.e. hospital
care record system) and regional resources (i.e. NHS
Health and Social Care Information Centre Spine Ser-
vices) will ensure that only surviving patients receive a
questionnaire.
Cessation of study care (haemostasis)
For the purposes of this comparative study, haemostasis
(end of study care) will be defined as the point 1 h from
the last administration of RBC and the treating clinician
believes that primary haemostasis has been achieved.
Procedure for data collection
Study subject data will be captured locally using a paper
Case Report Form (CRF), following local data security
routines. CRF data are transferred and uploaded to a
centralised study database whereupon study data integ-
rity is reviewed weekly by the Trial Coordinating Centre.
Adverse event reporting
Patients included in this trial have a high risk of morbid-
ity and mortality, with either treatment being adminis-
tered during a phase of critical bleeding and circulatory
failure. Therefore, patients have a very high risk of ex-
periencing several adverse events (AEs) and serious ad-
verse events (SAEs). All SAEs, expected or not, will be
recorded on a SAE form. Any SAE, death or thrombo-
embolic or ischaemic events (myocardial infarction,
stroke, pulmonary embolus, DVT) that are considered
to be ‘related’ and unexpected are to be reported to the
sponsor within 24 h, and to the Main Research Ethics
Committee (MREC) within 15 days in line with the re-
quired timeframe.
Urgent safety measures
The chief investigator (CI) will take urgent safety mea-
sures to ensure the safety and protection of the clinical
trial subjects from any immediate hazard to their health
and safety. The measures should be taken immediately.
In this instance, the approval of the Ethics Committee
prior to implementing these safety measures is not re-
quired. However, it is the responsibility of the CI to in-
form the sponsor and the Main Research Ethics
Committee (MREC) (via telephone) of this event
immediately.
The CI has an obligation to inform both the MREC in
writing within 3 days, in the form of a substantial
amendment. The sponsor (Joint Research Management
Office (JRMO)) must be sent a copy of the correspond-
ence with regards to this matter.
Annual safety reporting
The CI will send the Annual Progress Report to the
MREC using the NRES template (the anniversary date is
the date on the MREC ‘favourable opinion’ letter from
the MREC) and to the sponsor.
Subject withdrawal
Every reasonable effort will be made to maintain proto-
col compliance and to retain patient participation in the
study, consistent with the provisions of informed con-
sent and good clinical practice. The following are poten-
tial reasons why a patient may be withdrawn from the
study:
1. Withdrawal of consent/agreement
2. Retrospective exclusion: if a patient is deemed to not
meet one or more of the inclusion/exclusion criteria
in retrospect they will be withdrawn from the study
3. Major protocol deviation from the study design by
the subject, observed or suspected by the
investigator
4. Administrative: the sponsor or monitoring
committees decide to terminate or discontinue the
study
5. The subject’s health would be jeopardised by
continued participation and hence will be withdrawn
at the discretion of the investigator
The study withdrawal form will be completed for these
patients and a reason for withdrawal captured. All sub-
ject’s withdrawn from the study will be managed in ac-
cordance with the hospital’s standard procedures.
Data collection and follow-up for withdrawn subjects
Patients who withdraw from the study after randomisa-
tion will be followed for safety by conducting safety as-
sessments through to the end of day 28. If a patient who
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withdraws has an ongoing SAE every effort must be
made to follow up such events until satisfactory reso-
lution is obtained or until further follow-up is no longer
warranted.
Subject replacement
Subjects who withdraw from the study will be replaced.
End of study definition
The study will be considered closed when all surviving
subjects complete in-hospital safety and outcome moni-
toring. This includes: safety measures of SAE rate within
28 days, total hospital stay, total critical care stays, 28-
day ventilator-free days and 28-day mortality
Statistical considerations
Sample size
Based upon legacy registry data from the partners, ap-
proximately 28% of patients will need massive transfu-
sion or die. It is expected that this figure will decrease to
an overall proportion of 15% in the VHA group (i.e.
using VHA-guided strategy). In order to detect a differ-
ence from 28% to 15% with a power of 80% and a two-
sided alpha of 0.05, 170 patients per group are required.
One hundred and ninety-six patients per study arm al-
lows a 13% dropout rate, with an allocation ratio of 1.
The planned sample size for this study is 392 patients
for which MTP is activated and transfusions initiated,
196 in each study arm.
Method of analysis
All primary and secondary outcomes will be analysed as
intention-to-treat, and will include all randomised pa-
tients for whom the primary outcome of ‘alive’ and ‘free
of massive transfusion’ at 24 h is recorded. The primary
endpoint of patients who are alive and free of massive
transfusion at 24 h will be assessed by difference in pro-
portion with 95% confidence intervals. The chi-square
test or Fischer’s exact test will be used were appropriate.
Absolute risk reduction and relative risk reduction by
VHA-guided therapy will be calculated.
Kaplan-Meier mortality estimates between the two
arms for all-cause mortality at 6 and 24 h, as well as 28
and 90 days post admission, will be estimated for the
secondary endpoint of death.
A per-protocol analysis and a sensitivity analysis will
be performed for the primary endpoint. The following
patients will be excluded from the per-protocol analysis:
 Patients who do not have at least one ROTEM®/
TEG®/CCT test performed and
 Who die within 60 min after baseline blood
sampling or
 Who achieve haemostasis within 60 min of baseline
sampling
Both ROTEM®-guided and TEG®-guided therapy to-
gether (i.e. the VHA arm) will be compared with the
CCT arm. Separate analyses will be performed for
ROTEM®-guided and TEG®-guided therapy alone for pri-
mary endpoints and correction of coagulopathy.
All applied tests will be two-sided and p values of 0.05
will be accepted as statistically significant. We will report
p values with and without correction for multiple
testing.
Subgroup analyses
The following patient categories will be included in all
primary and secondary analyses but will also be analysed
separately as subgroup analyses:
 Patients with known pre-existing coagulopathy
 Oral anticoagulant therapy (except for aspirin)
 Excluding patients with severe traumatic brain
injury (AIS brain 4,5 or 6)
 Patients who arriving in a coagulopathic state
(PTr > 1.2)
 Patients who received a massive transfusion (10 or
more RBC units in the first 24 h)
Sensitivity analyses
Missing data are not expected for the primary outcome.
Sensitivity analysis for secondary outcomes will be
assessed using 100 multiple imputations for missing
data. Rubin rules will be used to summarise the results
of the multiple imputations.
Integrated cost-effectiveness analysis
A cost-effectiveness analysis will be conducted to assess
the costs and effects of VHA-guided therapy versus
those of optimised empiric treatment. A model will be
developed which will be structured around the key clin-
ical time points and events in the early management
pathway of bleeding trauma patients.
The two treatment policies will be compared in terms
of their estimated costs and effects (quality-adjusted life
years (QALYs): calculated by combining survival and
HRQoL data) and incremental analyses will be per-
formed. If VHA-guided therapy is more effective but
also more costly than empirical treatment, then the in-
cremental cost-effectiveness ratio (ICER) will be calcu-
lated. The ICER is calculated by dividing the difference
in costs between VHA and empirically guided therapy
by the difference in effects (QALYs) and gives the add-
itional cost of generating one additional unit of outcome
(here, a QALY).
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So as to account for the uncertainty in the model in-
put data, parameters will be entered as distributions ra-
ther than point estimates. Probabilistic sensitivity
analysis will be used to take repeated random draws
from all distributions simultaneously, each time recalcu-
lating the model’s results for a total of 2000 times. The
uncertainty will be summarised on the cost-effectiveness
plane and using cost-effectiveness acceptability curves.
For each country, the modelling exercise should provide
an estimate of the probability that VHA-guided therapy
is likely to be cost-effective when compared with opti-
mised empiric treatment.
Monitoring and quality assurance
Summary monitoring plan
Data coordination and site management services will be
performed at the sponsor institution, Queen Mary Uni-
versity of London. The site clinical trials coordinator will
perform regular monitoring of trial documentation and
CRFs.
Safety analysis
A pre-defined interim analysis will be performed after
the enrolment of 100 patients, including an assessment
of recruitment logistics with the possibility to revise the
planned sample size.
A Data Safety Monitoring Board (DSMB) will review
all data on outcome of the patients in the respective
treatment arms. The DSMB will focus on adherence to
protocol, and present pre-specified criteria that need to
be fulfilled with regard to patient safety for the study to
continue.
Audit and inspection
For the purpose of compliance with Good Clinical Prac-
tice (GCP) and Regulatory Agency Guidelines it may be
necessary for the sponsor or a drug regulatory agency to
conduct a site audit. This may occur at any time from
the start to after conclusion of the study.
Discussion
TIC is present early after injury in a significant propor-
tion of patients [3–5], and is associated with increased
bleeding, greater risk of complications and increased
mortality, underlining the importance of early detection
and aggressive treatment [4, 6, 7, 22].
Improvements in transfusion strategies over the last
decade are associated with better outcome [23–26]. The
results of the PROPPR trial [19] provide the best evi-
dence to date for ratio-based trauma resuscitation. In
that study, a MTP aiming at a 1:1:1 ratio of plasma 1:
platelets 1: RBC 1 until haemorrhage control was associ-
ated with better outcome than a 1:1:2 ratio. However,
PROPPR did not allow adjustments in the individual
treatment based on results from coagulation tests during
the course of resuscitation.
Traditionally, CCTs such as prothrombin time/inter-
national normalised ratio (PT/INR), activated partial
thromboplastin time (aPTT), fibrinogen concentration
and PLT have been recommended to guide resuscita-
tion in bleeding trauma patients [27]. However, none
of the existing CCTs have proven to be robust in de-
tecting TIC or predicting massive transfusion. More-
over, CCTs are time-consuming laboratory tests only
reflecting the initial steps of blood coagulation and
not taking into account the interaction between plate-
lets and coagulation factors.
On that background, the potential benefit of Viscoelas-
tic Haemostatic Assays (VHAs), such as TEG® and
ROTEM®, in the trauma setting has gained much atten-
tion over the last decade. VHAs are dynamic tests; they
may be performed bedside with their first results avail-
able within minutes of initiation. Several algorithms for
guiding resuscitation in bleeding trauma patients based
on VHA parameters have been published [28, 29]. None
of them have been developed based on real-time large
cohorts of trauma patients.
The updated European guidelines addressing the man-
agement of bleeding and coagulopathy following major
trauma recommend the use of viscoelastic methods to
assist in characterising the coagulopathy and in guiding
haemostatic therapy [27] although the evidence to sup-
port the use of VHAs in this category of patients is in-
sufficient [15–18].
Based on limited existing evidence to support the use
of VHA versus CCTs in monitoring the resuscitation of
massively bleeding trauma patients, our aim is to evalu-
ate the differences between VHA-guided and CCT-
guided transfusion in trauma patients, and to create ro-
bust evidence-based guidelines for massive transfusion
in trauma patients.
iTACTIC has obvious limitations, based on the actual
level of evidence in this field. The challenges include the
heterogeneity of, and access to, a population of severely
injured patients as well as the development of relevant
algorithms. Strength and weaknesses will be fully ad-
dressed when the trial results are published.
Trial status
This study is ongoing and started recruiting June 2016.
Recruitment will be completed mid 2018.
Additional files
Additional file 1: Protocol version 3.0/14.03.2017. (PDF 2172 kb)
Additional file 2: SPIRIT Checklist. (DOC 129 kb)
Additional file 3: SOFA score. (ZIP 217 kb)
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